Atorvastatin - Medlab

Drug Profile

Atorvastatin - Medlab

Latest Information Update: 11 Aug 2016

Price : $50

At a glance

  • Originator Medlab
  • Class Amides; Antihyperlipidaemics; Fatty acids; Fluorobenzenes; Heptanoic acids; Pyrroles; Small molecules
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypercholesterolaemia

Most Recent Events

  • 01 Jan 2015 Preclinical trials in Hypercholesterolaemia in Australia (Buccal) (ACTRN12615001285549)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top